Список литературы

Внимание! Часть функций, например, копирование текста к себе в конспект, озвучивание и т.д. могут быть доступны только в режиме постраничного просмотра.

49. Facchinetti F., Dante G., Neri I. The Ratio of MI to DCI and Its Impact in the Treatment of Polycystic Ovary Syndrome: Experimental and Literature Evidences // Front. Gynecol. Endocrinol. 2016; 3: 103–109.

50. Unfer V., DiNicola S., Laganà A.S., Bizzarri M. Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS // Int. J. Mol. Sci. 2020; 21: 7157.

51. Kalra B., Kalra S., Sharma J.B. The inositols and polycystic ovary syndrome. Indian J. Endocrinol. Metab. 2016; 20: 720–724.

52. Carlomagno G., Unfer V., Roseff S. The D-chiro-inositol paradox in the ovary // Fertil. Steril. 2011; 95: 2515–2516.

53. Laganà A.S., Rossetti P., Buscema M., La Vignera S., Condorelli R.A., Gullo G., Granese R., Triolo O. Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols // Int. J. Endocrinol. 2016; 2016: 1–9.

54. Facchinetti F. et al., Results from the International Consensus Conference on Myo-inositol and D-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS European Journal of Obstetrics & Gynecology and Reproductive Biology. October 2015.

55. Sortino M.A., Salomone S., Carruba M.O., Drago F. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols // Front. Pharmacol. 2017; 8: 341.

56. Чернуха Г.Е., Табеева Г.И., Удовиченко М.А. Неиспользованные возможности коррекции эндокринно-метаболических нарушений при синдроме поликистозных яичников // Акушерство и Гинекология. 2019. № 10. С. 144–151.

57. Persson S., Elenis E., Turkmen S., Kramer M.S., Yong E.L., Sundstrom-Poromaa I. Fecundity among women with polycystic ovary syndrome (PCOS)-a population-based study. Hum. Reprod. 2019.

58. Palomba S., de Wilde M.A., Falbo A., Koster M.P., La Sala G.B., Fauser B.C. Pregnancy complications in women with polycystic ovary syndrome // Hum. Reprod. Update 2015; 21: 575–592.

59. Yu H.F., Chen H.S., Rao D.P., Gong J. Association between polycystic ovary syndrome and the risk of pregnancy complications: A PRISMA-compliant systematic review and meta-analysis // Medicine (Baltimore). 2016; 95: e4863.

60. Bahri Khomami M., Boyle J.A., Tay C.T., Vanky E., Teede H.J., Joham A.E., Moran L.J. Polycystic ovary syndrome and adverse pregnancy outcomes: Current state of knowledge, challenges and potential implications for practice // Clin. Endocrinol. (Oxf.). 2018; 88: 761–769.

61. Bahri Khomami M., Joham A.E., Boyle J.A., Piltonen T., Silagy M., Arora C., Misso M.L., Teede H.J., Moran L.J. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-A systematic review, meta-analysis, and meta-regression // Obesity Reviews. 2019; 20: 659–674.

62. Shand A.W., Whitton K., Pasfield A., Nassar N., McShane M., Han X., Henry A. Evaluation of anti-Mullerian hormone in the first trimester as a predictor for hypertensive disorders of pregnancy and other adverse pregnancy outcomes // Aust. N. Z. J. Obstet. Gynaecol. 2014; 54: 244–249.

63. Valdimarsdottir R., Valgeirsdottir H., Wikstrom A.K., Kallak T.K., Elenis E., Axelsson O., Ubhayasekhera K., Bergquist J., Piltonen T.T., Pigny P., Giacobini P., Poromaa I.S. Pregnancy and neonatal complications in women with polycystic ovary syndrome in relation to second-trimester anti-Mullerian hormone levels // Reprod. Biomed. Online. 2019.

64. Glintborg D., Jensen R.C., Bentsen K., Schmedes A.V., Brandslund I., Kyhl H.B., Bilenberg N., Andersen M.S. Testosterone Levels in Third Trimester in Polycystic Ovary Syndrome: Odense Child Cohort // J. Clin. Endocrinol. Metab. 2018; 103: 3819–3827.

65. Detti L., Christiansen M.E., Francillon L., Ikuwezunma G., Diamond M.P., Mari G., Tobiasz A.M. Serum Anti-Müllerian hormone (AMH) in mothers with polycystic ovary syndrome (PCOS) and their term fetuses // Syst. Biol. Reprod. Med. 2019; 65: 147–154.

66. Sharifzadeh F., Kashanian M., Fatemi F. A comparison of serum androgens in preeclamptic and normotensive pregnant women during the third trimester of pregnancy // Gynecol. Endocrinol. 2012; 28: 834–836.

67. Tuutti E.K., Hamalainen E.K., Sainio S.M., Hiilesmaa V.K., Turpeinen U.L., Alfthan H.V., Stenman U.H. Serum testosterone levels during early pregnancy in patients developing preeclampsia // Scand. J. Clin. Lab. Invest. 2011; 71: 413–418.

68. Carlsen S.M., Jacobsen G., Romundstad P. Maternal testosterone levels during pregnancy are associated with offspring size at birth // Eur. J. Endocrinol. 2006; 155: 365–370.

69. Cho J., Su X., Holditch-Davis D. Associations of Maternal Testosterone and Cortisol Levels With Health Outcomes of Mothers and Their Very-Low-Birth weight Infants // Biol. Res. Nurs. 2017; 19: 409–418.

70. Kallak T.K., Hellgren C., Skalkidou A., Sandelin-Francke L., Ubhayasekhera K., Bergquist J., Axelsson O., Comasco E., Campbell R.E., Sundstrom Poromaa I. Maternal and female fetal testosterone levels are associated with maternal age and gestational weight gain // Eur. J. Endocrinol. 2017; 177: 379–388.

71. Novembri R., Funghi L., Voltolini C., Belmonte G., Vannuccini S., Torricelli M., Petraglia F. Placenta expresses anti-Müllerian hormone and its receptor: Sex-related difference in fetal membranes // Placenta 2015; 36: 731–737.

72. Kollmann M., Klaritsch P., Martins W.P. et al. Maternal and neonatal outcomes in pregnant women with PCOS: comparison of different diagnostic definitions // Hum Reprod. 2015; 30(10): 2396–2403.

73. Doherty D.A., Newnham J.P., Bower C. et al. Implications of polycystic ovary syndrome for pregnancy and for the health of offspring // Obstet Gynecol. 2015; 125(6): 1397–1406.

74. Joham A.E., Palomba S. and Hart R. Polycystic ovary syndrome, obesity, and pregnancy // Semin Reprod Med. 2016. 34(2): 93–101.

75. Sterling L., Liu J., Okun N. et al. Pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization // Fertil Steril. 2016; 105(3): 791–797.e2.

76. Sawada M., Masuyama H., Hayata K. et al. Pregnancy complications and glucose intolerance in women with polycystic ovary syndrome // Endocr J. 2015; 62(11): 1017–1023.

77. Santamaria A., Di Benedetto A., Petrella E., Pintaudi B., Corrado F., D’Anna R., Neri I., Facchinetti F. Myo-inositol may prevent gestational diabetes onset in overweight women: A randomized, controlled trial // J. Matern. Neonatal Med. 2015; 29: 3234–3237.

78. D’Anna R., Di Benedetto A., Scilipoti A., Santamaria A., Interdonato M.L., Petrella E., Neri I., Pintaudi B., Corrado F., Facchinetti F. Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial // Obstet. Gynecol. 2015; 126: 310–315.

79. D’Anna R., Di Benedetto V., Rizzo P., Raffone E., Interdonato M.L., Corrado F. Myo-inositol may prevent gestational diabetes in PCOS women // Gynecol. Endocrinol. 2012; 28: 440–442.

80. Corrado F., D’Anna R., Di Vieste G., Giordano D., Pintaudi B., Santamaria A., Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes // Diabet. Med. 2011; 28: 972–975.